The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Clinically relevant advances that have been made in HL biology and the value of ctDNA
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, comments on significant advances made in Hodgkin lymphoma (HL) biology over the past 25 years. He also highlights the value of circulating tumor DNA as a disease monitoring tool. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
